March 12, 2004

Repetitive Cycles of High-Dose Cytarabine Benefit Patients With Acute Myeloid Leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461

Key Points

Key points are not available for this paper at this time.

Abstract

We conclude that, in AML patients with inv(16)/t(16;16), repetitive HDAC therapy decreases the likelihood of relapse compared with consolidation regimens including less HDAC.

AIに質問

Bookmark

Cite This Study

Byrd et al. (Fri,) studied this question.

synapsesocial.com/papers/69df3ab7d5404a0bea5926ab https://doi.org/https://doi.org/10.1200/jco.2004.07.012

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)2002 · 1,617 citations
2International System for Human Cytogenetic Nomenclature2020 · 6,882 citations
3Correlation of drug-perturbed marrow cell growth kinetics and intracellular 1-B-D-arabinofuranosylcytosine metabolism with clinical response in adult acute myelogenous leukemia1987 · 25 citations
4Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside.1994 · 57 citations
5Evaluation of leukemic cell chromosomes as a guide to therapy.1982 · 11 citations

AIに質問

Bookmark